1 Genetic Polymorphisms and Post-Stroke Upper Limb Motor Improvement – A Systematic

- 2 Review and Meta-Analysis
- 3
- 4 Sandeep K. Subramanian,^{1,2,3,4*} Riley T. Morgan,¹ Carl Rasmusson,¹ Kayla M. Shepherd,¹ Carol
- 5 $L L i^{3,5}$
- 6
- ⁷ ¹Department of Physical Therapy, School of Health Professions, University of Texas Health
- 8 Science Center at San Antonio, San Antonio, TX, USA.
- 9 ²Department of Physician Assistant Studies, School of Health Professions, University of Texas
- 10 Health Science Center at San Antonio, San Antonio, TX, USA.
- ³Department of Rehabilitation Medicine, Long School of Medicine, University of Texas Health
- 12 Science Center at San Antonio, San Antonio, TX, USA.
- 13 ⁴Center for Biomedical Neurosciences, University of Texas Health Science Center at San
- 14 Antonio, San Antonio, TX, USA.
- ⁵Audie L. Murphy VA Hospital, South Texas Veterans Health Administration, Polytrauma
- 16 Rehabilitation Center, San Antonio, TX, USA.
- 17
- 18 *Corresponding Author:
- 19 Sandeep K Subramanian, PT, Ph.D
- 20 Assistant Professor,
- 21 Department of Physical Therapy,
- 22 School of Health Professions,
- 23 UT Health San Antonio,
- 24 San Antonio, Texas,

GENETIC POLYMORPHISM AND UL REHABILITATION

SUBRAMANIAN ET AL

- 25 USA 78229
- 26 Phone: 1-210-567-8762
- 27 Fax: 1-210-567-8774
- 28 Email: subramanias3@uthscsa.edu

- 30 Keywords: arm, cerebrovascular accident, BDNF, CoMT, APOE, outcome, rehabilitation, genes
- 31
- 32 Word Count: 3662 words
- 33
- 34 ORCID: Sandeep K Subramanian: 0000-0002-5972-1588

GENETIC POLYMORPHISM AND UL REHABILITATION

SUBRAMANIAN ET AL

35 Abstract:

00	
37	Background: Post-stroke upper limb (UL) motor improvement is associated with adaptive
38	neuroplasticity and motor learning. Both intervention-related (including provision of intensive,
39	variable, and task-specific practice) and individual-specific factors (including the presence of
40	genetic polymorphisms) influence improvement. In individuals with stroke, most commonly,
41	polymorphisms are found in Brain Derived Neurotrophic Factor (BDNF), Apolipoprotein
42	(APOE) and catechol-O-methyltransferase (COMT). These involve a replacement of cystine by
43	arginine (APOEɛ4) or one or two valines by methionine (BDNF: val ⁶⁶ met, COMT: val ¹⁵⁸ met).
44	However, the implications of these polymorphisms on post-stroke UL motor improvement
45	specifically have not yet been elucidated.
46	
47	Objective: Examine the influence of genetic polymorphism on post-stroke UL motor
48	improvement.
49	
50	Design: Systematic Review and Meta-Analysis
51	
52	Methods: We conducted a systematic search of the published literature in English language of
53	using standard methodology. The modified Downs and Black checklist helped assess study
54	quality. We compared change in UL motor impairment and activity scores between individuals
55	with and without the polymorphisms. Meta-analyses helped assess change in motor impairment
56	scores based upon a minimum of two studies per time point. Effect sizes (ES) were quantified

GENETIC POLYMORPHISM AND UL REHABILITATION

SUBRAMANIAN ET AL

- based upon the Rehabilitation Treatment Specification System as follows: small (0.08–0.18),
 medium (0.19–0.40) and large (≥0.41).
- 59
- 60 **Results:** We retrieved 10 (four good and six fair quality) studies. Compared to those with BDNF
- 61 val⁶⁶met polymorphism, meta-analyses revealed lower motor impairment scores (large ES) in
- 62 those without the polymorphism at intervention completion (0.5, 95% CI: 0.11-0.88) and at
- 63 retention (0.58, 95% CI: 0.06-1.11). Presence of CoMT val¹⁵⁸met polymorphism had similar
- for results, with higher levels of improvement in impairment (large ES \geq 1.5) and activity scores
- 65 (large ES ranging from 0.5-0.76) in those without the polymorphism. Presence of APOEɛ4 form
- 66 did not influence UL motor improvement.
- 67
- 68 Conclusion: BDNF val⁶⁶met and COMT val¹⁵⁸met polymorphisms negatively influence UL
- 69 motor improvement in impairment and activity scores.
- 70
- 71 **Registration:** https://osf.io/wk9cf/

GENETIC POLYMORPHISM AND UL REHABILITATION

SUBRAMANIAN ET AL

72 Introduction

73

74	Stroke continues to be a leading cause of adult morbidity in the United States. ¹ One of the
75	most disabling aftereffects of a stroke is the presence of upper limb (UL) hemiparesis. A large
76	proportion of stroke survivors present with UL sensorimotor impairments on the paretic side,
77	reduced independence in performance of daily life activities (ADL) and restricted participation. ²
78	Along with spontaneous recovery mechanisms, ³ motor improvement of the paretic side enabling
79	successful task-performance is attributable to adaptive neuroplasticity and motor learning. ⁴
80	
81	Successful task-performance entails an interaction of the individual, environment, and the
82	task to be performed. ⁵ The role of the environment ^{6,7} and factors influencing task-practice ⁸ have
83	been extensively studied. Recently, there is a renewed focus on the role of individual-specific
84	characteristics such as levels of motivation, ^{9,10} mood ¹⁰ and the role of biomarkers. ¹¹ Bernhardt et
85	al ¹² defined biomarkers as "indicators of disease state that can be used clinically as a measure
86	reflecting underlying molecular and cellular processes that may be difficult to measure directly
87	in humans and could be used to predict recovery or treatment response." Biomarker studies
88	within the realm of neurorehabilitation include those based on biology (e.g., genetics), structural
89	and/or imaging ¹³ and neurophysiological markers ¹⁴ of central nervous system excitability and
90	electrical activity.

91

92 The role of imaging-based biomarkers of structural and functional corticospinal tract
 93 connectivity alone¹³ or in combination with neurophysiological markers (e.g. motor evoked
 94 potential amplitude)¹⁴ has been extensively studied. The role of genetics-based biomarkers is

GENETIC POLYMORPHISM AND UL REHABILITATION

SUBRAMANIAN ET AL

95	slowly gaining prominence, ¹⁵ with studies focusing on single nucleotide polymorphisms
96	(SNPs). ¹¹ These SNPs can alter the basic functioning in cellular and molecular processes ¹⁶ and
97	tend to influence functional improvement produced by environmental interaction and in response
98	to rehabilitation interventions. ¹⁷ Genetics-based biomarkers identified as pertinent to stroke
99	recovery include SNPs in brain-derived neurotrophic factor (BDNF), Catechol-o-
100	methyltransferase (COMT) and Apolipoprotein (APOE). ¹¹
101	
102	An activity dependant ¹⁸ neurotrophin important for neuroplasticity and protection after
103	injury, BDNF facilitates synaptic transmission and long-term potentiation important for motor
104	learning. ¹⁹ A common SNP that occurs in BDNF is substitution of one or two valines at codon 66
105	with methionine due to substitution of adenine in place of guanine at nucleotide 196. ²⁰ The
106	polymorphism reduces activity-dependent BDNF release, ²¹ and results in altered neuroplasticity
107	and learning in healthy controls ²² and after a stroke. ^{23,24}
108	
109	The COMT enzyme helps degrade and thus influences the availability of Dopamine in
110	the central nervous system. ²⁵ . Dopamine can influence post-stroke motor learning and
111	improvement. ^{26,27} A commonly observed SNP results in a change from valine or methionine at
112	codon 158 (in the membrane form) and codon 108 in the soluble form, which results in a 3-4 fold
113	decrease in COMT activity. ^{28,29} The role of COMT polymorphism has primarily been assessed
114	on motor learning in Parkinson's disease ^{30,31} and severe Schizophrenia. ³² Given that COMT is
115	found in areas essential for motor learning, ³³ such as striatum and motor cortex, ³⁴ the effects of
116	COMT polymorphism on post-stroke motor improvement need to be addressed.
117	

GENETIC POLYMORPHISM AND UL REHABILITATION

SUBRAMANIAN ET AL

118	Although involved in lipid transport between cells, APOE helps modulate neuronal repair
119	and regeneration of nervous tissue. One of the alleles of APOE is the Epsilon-4 form (ϵ 4) with
120	arginine at positions 112 and 158 in place of cystine. Presence of APOE-ɛ4 can cause reduced
121	hippocampal volume and cortical thickness, cognitive impairments ³⁵ and lower recovery levels
122	after traumatic brain ³⁶ and spinal cord ³⁷ injuries. After a stroke, previous meta-analyses ^{38,39}
123	revealed lower improvement after sub-arachnoid hemorrhage in those with the $\varepsilon 4$ form, but no
124	association with improvements after ischemic strokes. In both studies, ^{38,39} motor improvements
125	were assessed using generic scales such as the modified Rankin Scale (mRS). Improved scores in
126	assessments such as the mRS does not specifically represent UL motor improvement. ⁴⁰ As
127	presence of cognitive impairments influence UL motor improvement, ⁴¹ the effects of the APOE-
128	ε4 form on post-stroke UL motor improvements needs to be systematically evaluated.
129	
130	The role of genetic polymorphisms has previously been reviewed. ^{11,16,24,39,42,43} These
131	studies were either narrative reviews ^{11,16,24,43} or meta-analyses including global stroke outcomes
132	like National Institutes of Health Stroke Scale and/or mRS. ^{39,42} Post-stroke UL motor
133	improvement continues to remain variable and less than optimal in many cases. ⁴⁴ Evaluation of
134	whether and to what extent genetic polymorphisms influence the extent of improvement may

136 examined the influence of genetic polymorphisms on UL motor improvement. The question

help explain some of the observed variability. Using a systematic review and meta-analysis, we

137 guiding our review was "In individuals with post-stroke UL hemiparesis, does the presence,

138 *compared to the absence of genetic polymorphisms, influence motor improvement?*" Preliminary

139 results have previously appeared as an abstract.⁴⁵

140

135

GENETIC POLYMORPHISM AND UL REHABILITATION

SUBRAMANIAN ET AL

141 Methods

142

This systematic review followed the PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) guidelines. The protocol was registered on the Open Science
Framework (https://osf.io/wk9cf/).

146

147 We searched the literature for studies involving human subjects published in English 148 between the years 2000 and 2023. The last search was conducted in September 2023. Key search 149 terms used included: stroke, cerebrovascular accident, upper limb, arm, rehabilitation, impairment, activities of daily living, recovery, polymorphisms, gene*, neuroplasticity, and 150 151 motor learning. Databases searched included: PubMed and ISI Web of Science and the Google 152 Scholar repository. We included studies that used clinical assessments of UL motor impairment 153 and/or ADL and provided data for individuals with and without polymorphisms. We excluded 154 studies focusing exclusively on lower limb or on only cognitive outcomes. We also excluded 155 other reviews, although we searched the reference lists of these excluded reviews for pertinent 156 citations. To identify additional relevant articles, we also searched reference lists of each 157 retrieved study.

158

159 Data Abstraction

We grouped the retrieved articles according to the polymorphism examined. We developed and used a data abstraction form to extract data from the selected articles. Data were initially extracted by RTM, CR and KMS. The first author (SKS) then verified that all relevant data were obtained from the selected articles. The extracted data included details about

GENETIC POLYMORPHISM AND UL REHABILITATION

SUBRAMANIAN ET AL

- 164 chronicity, distribution of sample based upon those with and without polymorphism, details
- about the intervention, outcomes used to assess change and the study results.
- 166
- 167 *Study quality assessment*
- We assessed the quality of the selected articles using the modified version⁴⁶ of the 168 reliable and valid Downs and Black (D&B) checklist.⁴⁷ The D&B checklist can be used to assess 169 170 the quality of both randomized and non-randomized study designs. The total scores of this 171 assessment and PEDro scale are highly correlated in studies involving post-stroke participants.⁴⁸ According to available guidelines,⁴⁹ we classified the scores as "excellent" (score 24-28), "good" 172 (score 19-23), "fair" (score 14-18), or "poor" (score ≤ 13). The quality of each study was 173 174 independently evaluated by RTM, CR and KMS, with discrepancies, if any, resolved by SKS and 175 CLL.
- 176
- 177 Risk of Bias

The risk of bias (ROB) was estimated using the Cochrane ROB tool⁵⁰ and ACROBAT-178 179 NRSI (A Cochrane Risk Of Bias Assessment Tool: for Non-Randomized Studies of Interventions)⁵¹ for randomized and non-randomized studies respectively. The Cochrane ROB 180 181 tools assesses the following domains: sequence generation, allocation, concealment, blinding of 182 participants, personnel and outcome assessors, incomplete outcome data, selective outcome 183 reporting, and other sources of bias. For each domain, we assigned a judgment: Yes - indicating 184 low ROB, No - indicating a high ROB, and Unclear - indicating unclear or unknown ROB where reported details were insufficient to reach a conclusion. The ACROBAT-NRSI tool assesses bias 185 186 that can arise because of confounding, study participant selection, intervention measurement,

GENETIC POLYMORPHISM AND UL REHABILITATION

SUBRAMANIAN ET AL

- departures from intended interventions, missing data, outcome measurement and reported resultselection.
- 189
- 190 *Statistical analyses*

191	Descriptive statistics of the study populations were calculated as percentages of the total
192	sample. When an article reported the effect of a particular polymorphism at both the motor
193	impairment and activity limitation levels, they were considered separately. Meta-analyses
194	(RevMan 5) examined differences in Fugl-Meyer (FM) scores in groups with and without
195	polymorphism. Pooled effects of the polymorphisms were quantified with standardized mean
196	differences. ⁵² If at least two studies reported the effects of the polymorphism on change in FM
197	scores, we included them in the meta-analysis. ^{53,54} I^2 scores helped assess heterogeneity. ⁵⁵
198	

Given that a variety of interventions were employed in the different studies, we used the random effects models (irrespective of I^2 values). Effect sizes were categorized as small (0.08 -0.18), medium (0.19 - 0.40) and large (\geq 0.41), in accordance with the Rehabilitation Treatment Specification System recommendations.⁵⁶ Sensitivity analysis was carried out to assess the effect of provision of rehabilitation interventions. We conducted an additional analysis excluding any study that did not report details of rehabilitation interventions provided.

205

206 **Results**

The search and selection results are shown in the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) flow diagram. In total, 319 citations were
identified through database and registry searches (Figure 1). After removing duplicates, 187

GENETIC POLYMORPHISM AND UL REHABILITATION

SUBRAMANIAN ET AL

210	citations were screened, of which 16 were excluded. We sought 116 reports for retrieval and
211	assessed 31 for full text eligibility, which were experimental studies including outcomes related
212	to rehabilitation. We further excluded 21 studies, as they included lower limb and/or gait
213	outcomes or used generic measures such as the mRS, NIHSS and Barthel Index. Ten articles
214	assessing the effects of genetic polymorphisms on UL motor impairment and ADL performance
215	were included in the qualitative synthesis (Figure 1). The reference lists of these ten articles did
216	not yield any additional citations.
217	
218	Out of the 10 studies, eight examined the influence of BDNF val ⁶⁶ met and two addressed
219	the effects of COMT val ¹⁵⁸ met polymorphisms. Two of the eight studies assessing the effects of
220	BDNF val ⁶⁶ met polymorphism additionally examined effects of APOE ε4 polymorphism. Six ^{23,}
221	⁵⁷⁻⁶¹ of the eight articles addressing effects of BDNF polymorphism had available FM scores
222	assessed at the end of the intervention to be used for a meta-analysis. Two studies ^{59,60} also
223	included a retention assessment, with that data being included for a second meta-analysis.
224	Insert_Figure_1_here
225	
226	BDNF val ⁶⁶ met polymorphism
227	In total, 598 individuals (59.2% men, 40.8% women) sustaining a stroke participated in
228	the eight studies included in the qualitative analysis. The average age of the participants (mean \pm
229	SD) was 58.4 \pm 3.2 years A greater proportion of participants had sustained ischemic strokes
230	(79.7%) compared to hemorrhagic strokes (20.3%). The distribution of the more-affected side
231	was almost equal (50.7% right, 49.3% left). Four ^{57,61-63} of the included studies were ranked as
231	was almost equal (50.7% right, 49.3% left). Four ^{57,61-65} of the included studies were ranked

232 'good' and the reaming six^{23,58-60,64,65} 'fair' (Supplementary Table 1). Participants were either in

GENETIC POLYMORPHISM AND UL REHABILITATION

SUBRAMANIAN ET AL

233	the acute ^{57-60,64} or chronic ^{23,61} stage post-stroke. All participants had moderate-to-severe ⁶⁶ UL
234	motor impairment (FM score ≤49/66).
235	Insert_Table_1 and figure_2_near_here
236	
237	Table 1 presents a summary of studies evaluating the effects of BDNF polymorphism
238	with a focus on sample size, type and dose of rehabilitation provided (if any), main outcomes and
239	results. The sample size used for the Meta-analysis was 295 (no polymorphism: 101,
240	polymorphism: 194). Analysis revealed a <i>large</i> (0.50, 95% CI: 0.11 - 0.88, $p = 0.01$, $I^2 = 54\%$,
241	random effects model; Figure 2) effect size at the end of the intervention period for improvement
242	in UL FM scores in those without compared to those with the polymorphism. At retention
243	testing, the sample size used was 79 (no polymorphism: 19, polymorphism: 60,). We found a
244	similar large effect size (0.58, 95% CI: 0.06 - 1.11, $p = 0.03$, $I^2 = 0\%$, random effects model;
245	Figure 3).
246	Insert_Figure_3_near_here
247	
248	In addition to UL FM scores, other assessments at the body structure and function level
249	included use of functional magnetic resonance imaging (fMRI), diffusion tensor imaging (DTI)
250	and MRI. In terms of fMRI outcomes, lower ipsilesional activation volume and percentage signal
251	change were noted in individuals with the Met alleles as compared to the Val homozygous
252	individuals. ²³ Use of DTI revealed differences in radial and axial diffusion ⁵⁹ and fractional
253	anisotropy ⁶⁰ between individuals with and without met alleles. Individuals with met alleles also
254	had greater cerebral atrophy on MRI. ⁶²

GENETIC POLYMORPHISM AND UL REHABILITATION

SUBRAMANIAN ET AL

255	Sensitivity analysis included an additional meta-analysis being conducted with data from
256	five studies included in this analysis. The only study excluded ⁵⁹ provided no details on whether
257	and if so, how many sessions of any form of rehabilitation were provided to the participants.
258	The sample size used for this Meta-analysis was 260 (no polymorphism: 91, polymorphism: 169).
259	Analysis revealed a large (0.43, 95% CI: 0.01 - 0.86, $p = 0.046$, $I^2 = 57\%$, random effects model;
260	Figure 4) effect size at the end of the intervention period for improvement in UL FM scores in
261	those without compared to those with the polymorphism.
262	Insert_Figure_4_near_here
263	
264	<u>APOEE4 Polymorphism</u>
265	Table 2 presents a summary of studies evaluating the effects of APOEɛ4 and COMT
266	val ¹⁵⁸ met polymorphism. Two (good quality ^{61,62}) of the eight studies examining the effects of
267	BDNF val66met polymorphism also assessed the effects of APO ϵ 4 polymorphism. These two
268	studies included a total of 260 participants (61.5% men, 38.5% women). A greater proportion of
269	participants had sustained ischemic strokes (83.4%) compared to hemorrhagic strokes (16.7%).
270	The distribution of the more-affected side was equal (50 % right, 50% left).
271	
272	Both studies used the Wolf Motor Function Test - timed test (WMFT-tt) as the primary
273	outcome. No differences were noted between individuals with and without the polymorphism on
274	WMFT-tt scores (Table 2A). In addition, groups did not differ on the amount of change seen in
275	UL FM scores and self-reported levels of UL quality (assessed using the Motor Activity Log) ⁶¹
276	or in the amount of cerebral atrophy noted between groups. ⁶²

277

Insert_Table_2_near_here

GENETIC POLYMORPHISM AND UL REHABILITATION

SUBRAMANIAN ET AL

278 <u>COMT val¹⁵⁸met Polymorphism</u>

279	Two fair ^{63,65} quality studies including 157 participants (59.7% men, 40.3% women)
280	examined the influence of COMT val ¹⁵⁸ met polymorphism (53: no polymorphism, 104:
281	polymorphism). A greater proportion of participants had sustained ischemic strokes (83.8%)
282	compared to hemorrhagic strokes (16.2%). The distribution of the more-affected side was 46.8%
283	right side, 51.9 %, left side and 1.3% of the participants had bilateral strokes. The studies used
284	either the UL section of the Rivermead Motor Assessment (RMA) ⁶³ or the FMA. ⁶⁵
285	
286	Compared to those with met ¹⁵⁸ met, participants with val ¹⁵⁸ met allele (ES = 0.51) or
287	val ¹⁵⁸ val (ES = 0.76) distribution had greater recovery with large effect sizes on the UL section
288	of the RMA, at the end of the intervention period. Similar results were obtained for the FMA.
289	Individuals with val ¹⁵⁸ val distribution had greater recovery on the FMA at the end of the
290	intervention period (ES = 2.69), and at 3 (ES = 1.51) and 6 months (ES = 1.98) retention testing.
291	In addition, participants without the polymorphism improved more on other components of the
292	RMA scores ⁶³ including gross function, leg, and trunk function and higher FIM scores. ⁶⁵
293	
~~ (

294 *Risk of Bias:*

Overall, the risk of bias was low for all studies (*Supplementary Figure 1, Supplementary Table 2*), except one.⁵⁹ The ROB for this one study could not be ascertained for the domains of measurement of interventions and departures from intended interventions, as information on whether the participants received any intervention or not was missing.

299

GENETIC POLYMORPHISM AND UL REHABILITATION

SUBRAMANIAN ET AL

301 Discussion

302

322

303	Results from this systematic review and meta-analysis showed that the presence of some
304	genetic polymorphisms negatively influence post-stroke UL motor improvement. The meta-
305	analyses revealed that BDNF polymorphism negatively impacted UL motor improvement,
306	immediately after the end of the intervention period as well as at retention testing. Overall,
307	majority of the studies had low risk of bias, which lends further credence to these results.
308	Sensitivity analyses revealed that results continued to remain significant even with the exclusion
309	of the study where information on some domains of bias was not available.
310	
311	These results are in agreement to those found previously, ⁴² and extend those findings
312	more specifically to UL motor improvement and not just general recovery from a stroke. We also
313	found that while APO $\varepsilon 4$ polymorphism does not influence UL motor improvement, presence of
314	COMT val ¹⁵⁸ met polymorphism has a negative impact. Our results for APO ɛ4 agree partially
315	with those found previously, ³⁹ and go beyond those results by focusing on UL motor
316	improvement. To our knowledge, this is the first review which has systematically investigated
317	the effects of COMT polymorphism on post-stroke UL motor improvement.
318	
319	Study Quality Assessment
320	Of the ten articles included in the review, four ^{57, 61-63} were ranked as 'good' and the
321	reaming six ^{23, 58-60,64,65} 'fair'. We did not find any articles that could be categorized as being of

323 used the modified D&B checklist in this review, as both randomized and non-randomized study

'poor' quality. However, we also did not have any articles that were 'excellent' in quality. We

GENETIC POLYMORPHISM AND UL REHABILITATION

SUBRAMANIAN ET AL

designs were included. The modified D&B checklist score includes an assessment of internal and
external validity, reporting standards and sample size. Commonly non-reported details across
studies in this review include information on external validity (three questions) and on
power/sample size analysis. Inherent word limitations in manuscript length may often preclude
exclusion of such information in the main text. It is suggested that such information may be
reported at least as supplementary material to provide a better overview of the rationale behind
participant selection in the studies.

331

332 Interventions used and number of sessions

A variety of interventions were used amongst the various studies included in the review. 333 334 The interventions used included the use of rTMS along with traditional physical (PT) and occupational therapy (OT) sessions, ^{57,58} provision of traditional PT and OT sessions alone^{60,63, 64} 335 virtual reality platform along with robotic assistive devices,²³ commercial gaming solution (i.e., 336 Nintendo Wii),⁶¹ modified constraint induced movement therapy,⁶¹ and task-oriented UL 337 training.⁶² No details were provided for two studies.^{59,65} The above-mentioned interventions were 338 339 delivered at different intensities. Time spent in therapy was the most common metric used to denote intensity in the included studies. Time spent in therapy was either 60 minutes/day, ^{61,62} 90 340 minutes/day (outpatient rehabilitation phase)⁶⁴ or three hours/day.^{57,58,64} Therapy was provided 341 for 10 sessions over 2 weeks,^{57,58,61} 2-3 weeks^{23,60} or 30 sessions.⁶² Information on exact number 342 343 of sessions was not provided for the other studies.

344

Although time spent in therapy is one metric of intensity,⁶⁷ other metrics include numbers
of repetitions⁶⁸ as well as "*amount of physical and/or mental work put forth by the client*".⁶⁹

GENETIC POLYMORPHISM AND UL REHABILITATION

SUBRAMANIAN ET AL

347	Previous work involving healthy controls with BDNF polymorphism has shown that employing a
348	high number of repetitions (about 800 repetitions/session) for about five days can cause
349	significant changes in short-term plasticity even in those with the polymorphism. ⁷⁰ The minimal
350	number of repetitions/ session in individuals with BDNF and other polymorphisms that have also
351	sustained a stroke are currently unknown. Approaches similar to those used previously could be
352	employed to estimate the minimal number of repetitions to achieve a plateau in motor
353	performance in a single session. ^{71,72} Whether using a fixed number of repetitions results in better
354	UL motor improvement in post-stroke individuals with polymorphisms remains to be estimated.
355	
356	Outcomes used to assess improvement
357	A variety of outcomes were used to assess the effects of the different polymorphisms. At

358 the body structure and function level, in addition to the FMA, the Rivermead Motor Assessment, 359 MRI, fMRI and diffusion tensor imaging (DTI) were used. At the activity level, Box and Blocks 360 Test, Wolf Motor Function Test and Motor Activity Log helped specifically assess UL activity 361 performance, while outcomes including Barthel Index and Functional Independence measure 362 helped assess general activity performance. All the selected outcomes have well established psychometric properties^{73,74} and measures including the FMA, Functional Independence 363 364 Measure, Motor Activity Log, Rivermead Motor Assessment, and Wolf Motor Function Test are amongst recommended measures.⁷³ However, no study used any assessment at the participation 365 366 level. Hence the effects of the polymorphism at the participation level have not yet been assessed. If select core measures such as those recommended by previous publications^{75,76} are 367 368 used, the effects across the different levels of the ICF could be better understood. In addition, the 369 UL part of the FM does not account for the use of altered movement patterns.⁶⁶ It is currently

GENETIC POLYMORPHISM AND UL REHABILITATION

SUBRAMANIAN ET AL

- 370 unknown whether individuals with genetic polymorphisms use compensatory movement patterns371 for task completion.
- 372
- 373 *Influence of ethnicity*

374	Majority of the studies in this review emerged from Asia, particularly from South East
375	Asia, with only four studies ^{23,61-63} being conducted outside Asia. Amongst these four studies,
376	three ^{23,61,62} had detailed demographics available on ethnicity of the participants. Individuals
377	belonging to Asian Ethnicity already have poor outcomes after a stroke. ⁷⁷ There are some reports
378	that individuals of Asian Ethnicity tend of receive less rehabilitation services compared to
379	individuals from a Caucasian ethnicity and have higher rates of hospital readmission. ⁷⁸⁻⁸⁰ In
380	addition, in all the three biomarkers examined in this meta-analysis, individuals with Asian
381	ethnicity have higher rates of polymorphism. ⁸¹⁻⁸³ The presence of high rates of the polymorphism
382	can be an additional factor explaining the lower rates of post-stroke motor improvement seen in
383	this population. This information can likely play an important role in prediction of prognosis
384	after a stroke. Furthermore, it can also help make decisions as to whether and if so, the extent to
385	which provision of rehabilitation interventions need to differ for this population.

386

387 Limitations

388

We only included studies involving adult participants published in English (since no one
in the team was proficient in other languages). It might be possible that we missed studies
published in other languages. None of the studies had an explicit sample size calculation.
Information on baseline levels of depression and/or intake of anti-depression medication was

GENETIC POLYMORPHISM AND UL REHABILITATION

SUBRAMANIAN ET AL

available in only two studies.^{23, 63} Information on the presence of depression is essential, as the
 presence of genetic polymorphisms is an additional risk factor⁸⁴ for post-stroke depression and
 can influence the extent of UL motor improvement.¹⁰

396

397 Conclusion

398

399 Our review and meta-analyses results indicate that presence of genetic polymorphisms in 400 BDNF and COMT negatively impact post-stroke motor improvement. This is especially true at 401 the body-structure and function domain of the ICF. Our findings may contribute to the 402 understanding of one of the underlying mechanisms to help explain some variability in post-403 stroke UL motor improvement. This is valuable information for the means of tailoring a plan of 404 care, creating realistic goals, and providing relevant, individualized care to every patient. In 405 addition, new questions have been identified including does the i) use of a fixed number of 406 repetitions result in similar or better levels of UL motor improvement in individuals with genetic polymorphisms; ii) presence of COMT val¹⁵⁸met continue to influence motor improvement at 407 408 retention testing; iii) presence of genetic polymorphisms influence participation levels and iv) do 409 individuals with genetic polymorphisms use altered movement patterns and if so, to what extent. 410 Answers to these emergent questions can help better understand the influence of genetic 411 polymorphisms on post-stroke upper limb motor improvement.

412 **Declarations**

Ethics approval and consent to participate: Not applicable, as this manuscript is a
systematic review. However, ethics approval was obtained for all the studies included.

GENETIC POLYMORPHISM AND UL REHABILITATION

SUBRAMANIAN ET AL

415	•	Consent f	for	publication:	Not	applicable
-----	---	-----------	-----	--------------	-----	------------

- 416 *Author contributions:*
- 417 **Sandeep K Subramanian:** Conceptualization; Funding acquisition; Methodology; Project
- 418 administration; Formal Analysis, Supervision; Writing review & editing.
- 419 **Riley T Morgan:** Investigation, Formal Analysis, Data Curation, Writing Original draft.
- 420 **Carl Rasmusson:** Investigation, Formal Analysis, Data Curation, Writing Original draft.
- 421 **Kayla M Shepherd:** Investigation, Formal Analysis, Data Curation, Writing Original
- 422 draft.
- 423 **Carol L Li:** Conceptualization; Methodology; Writing review & editing.
- *Acknowledgments:* The authors would like to acknowledge the UT Health San Antonio
 Briscoe library for access to numerous databases.
- *Funding:* This project was funded by a pilot grant by the Center for Biomedical
- 427 Neurosciences, UT Health San Antonio
- *Competing interests:* The authors declare that there is no conflict of interest.
- Availability of data and materials: Not applicable
- 430

References

- 431
- Feigin VL, Vos T, Alahdab F, et al. Burden of Neurological Disorders Across the US From
 1990-2017: A Global Burden of Disease Study. *JAMA Neurol* 2021; 78: 165-176.
- 434 2. Winstein CJ, Stein J, Arena R, et al. Guidelines for adult stroke rehabilitation and recovery
- 435 A guideline for healthcare professionals from the American Heart Association/American
- 436 Stroke Association. *Stroke* 2016; 47: e98-e169.

GENETIC POLYMORPHISM AND UL REHABILITATION

SUBRAMANIAN ET AL

- 437 3. Cassidy JM, Cramer SC. Spontaneous and therapeutic-induced mechanisms of functional
 438 recovery after stroke. *Transl Stroke Res* 2017; 8: 33-46.
- 439 4. Buma F, Kwakkel G, Ramsey N. Understanding upper limb recovery after stroke. *Restor*
- 440 *Neurol Neurosci* 2013; 31: 707-722
- 441 5. Newell KM. Motor skill acquisition. *Annu Rev Psychol* 1991; 42: 213-237.
- 442 6. Subramanian SK, Lourenco CB, Chilingaryan G, et al. Arm motor recovery using a virtual
- reality intervention in chronic stroke: randomized control trial. *Neurorehabil Neural Repair*
- 444 2013; 27: 13-23.
- 445 7. White JH, Bartley E, Janssen H, et al. Exploring stroke survivor experience of participation
- in an enriched environment: a qualitative study. *Disabil Rehabil* 2015; 37: 593-600.
- Kleim JA. Neural plasticity and neurorehabilitation: teaching the new brain old tricks. *J Commun Disord* 2011; 44: 521-528.
- 449 9. Levy T, Christie LJ, Killington M, et al. "Just that four letter word, hope": stroke survivors'
- 450 perspectives of participation in an intensive upper limb exercise program; a qualitative
- 451 exploration. *Physiother Theory Pract* 2021: 1-15.
- 452 10. Subramanian SK, Chilingaryan G, Sveistrup H, et al. Depressive symptoms influence use
 453 of feedback for motor learning and recovery in chronic stroke. *Restor Neurol Neurosci*454 2015; 33: 727-740.
- 455 11. Stewart JC, Cramer SC. Genetic variation and neuroplasticity: Role in rehabilitation after
 456 stroke. *J Neurol Phys Ther* 2017; 41 Suppl 3: S17-S23.
- 457 12. Bernhardt J, Borschmann K, Boyd L, et al. Moving rehabilitation research forward:
- 458 Developing consensus statements for rehabilitation and recovery research. *Int J Stroke*

459 2016; 11: 454-458.

GENETIC POLYMORPHISM AND UL REHABILITATION

SUBRAMANIAN ET AL

- 460 13. Feng W, Wang J, Chhatbar PY, et al. Corticospinal tract lesion load: an imaging biomarker
 461 for stroke motor outcomes. *Ann Neurol.* 2015; 78: 860-870.
- 462 14. Connell LA, Smith MC, Byblow WD, et al. Implementing biomarkers to predict motor
- 463 recovery after stroke. *NeuroRehabilitation* 2018; 43: 41-50.
- 464 15. Musunuru K, Hickey KT, Al-Khatib SM, et al. Basic concepts and potential applications of
- 465 genetics and genomics for cardiovascular and stroke clinicians: a scientific statement from
- the American Heart Association. *Circ. Cardiovasc. Genet* 2015; 8: 216-242.
- 467 16. Pearson-Fuhrhop KM, Kleim JA, Cramer SC. Brain plasticity and genetic factors. *Top*
- 468 *Stroke Rehabil* 2009; 16: 282-299.
- 469 17. Uhm KE, Kim YH, Yoon KJ, et al. BDNF genotype influence the efficacy of rTMS in
 470 stroke patients. *Neurosci Lett* 2015; 594: 117-121
- 471 18. Langdon KD, Corbett D. Improved working memory following novel combinations of
 472 physical and cognitive activity. *Neurorehabil Neural Repair* 2012; 26: 523-532.
- 473 19. Mang CS, Campbell KL, Ross CJ, et al. Promoting neuroplasticity for motor rehabilitation
- 474 after stroke: considering the effects of aerobic exercise and genetic variation on brain475 derived neurotrophic factor. *Phys Ther* 2013; 93: 1707-1716.
- 476 20. Casey BJ, Glatt CE, Tottenham N, et al. Brain-derived neurotrophic factor as a model
- 477 system for examining gene by environment interactions across development. *Neuroscience*478 2009; 164: 108-120.
- 479 21. Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met polymorphism affects
- 480 activity-dependent secretion of BDNF and human memory and hippocampal function. *Cell*
- 481 2003; 112: 257-269.

GENETIC POLYMORPHISM AND UL REHABILITATION

- 482 22. McHughen SA, Rodriguez PF, Kleim JA, et al. BDNF val66met polymorphism influences
 483 motor system function in the human brain. *Cereb Cortex* 2010; 20: 1254-1262.
- 484 23. Kim DY, Quinlan EB, Gramer R, et al. BDNF Val66Met Polymorphism is related to motor
- 485 system function after stroke. *Phys Ther* 2016; 96: 533-539.
- 486 24. Balkaya M, Cho S. Genetics of stroke recovery: BDNF val66met polymorphism in stroke
- 487 recovery and its interaction with aging. *Neurobiol Dis* 2019; 126: 36-46.
- 488 25. Meyer-Lindenberg A, Kohn PD, Kolachana B, et al. Midbrain dopamine and prefrontal
- function in humans: interaction and modulation by COMT genotype. *Nat Neurosci* 2005; 8:
- **490 594-596**.
- 491 26. Floel A, Hummel F, Breitenstein C, et al. Dopaminergic effects on encoding of a motor
 492 memory in chronic stroke. *Neurology* 2005; 65: 472-474.
- 493 27. Cramer SC. Drugs to enhance motor recovery after stroke. *Stroke* 2015; 46: 2998-3005.
- 494 28. Lachman HM, Papolos DF, Saito T, et al. Human catechol-O-methyltransferase
- 495 pharmacogenetics: description of a functional polymorphism and its potential application to
 496 neuropsychiatric disorders. *Pharmacogenetics* 1996; 6: 243-250.
- 497 29. Egan MF, Goldberg TE, Kolachana BS, et al. Effect of COMT Val108/158 Met genotype
- 498 on frontal lobe function and risk for schizophrenia. *Proc Natl Acad Sci U S A* 2001; 98:
- **499 6917-6922**.
- 500 30. Pearson-Fuhrhop KM, Minton B, Acevedo D, et al. Genetic variation in the human brain
- 501 dopamine system influences motor learning and its modulation by L-Dopa. *PLoS One*
- 502 2013; 8: e61197. DOI: 10.1371/journal.pone.0061197.

GENETIC POLYMORPHISM AND UL REHABILITATION

SUBRAMANIAN ET AL

- 503 31. Yin Y, Liu Y, Xu M, et al. Association of COMT rs4680 and MAO-B rs1799836
- 504 polymorphisms with levodopa-induced dyskinesia in Parkinson's disease-a meta-analysis.
- 505 *Neurol Sci* 2021. DOI: 10.1007/s10072-021-05509-3.
- 506 32. Galderisi S, Maj M, Kirkpatrick B, et al. Catechol-O-methyltransferase Val158Met
- 507 polymorphism in schizophrenia: associations with cognitive and motor impairment.
- 508 *Neuropsychobiology* 2005; 52: 83-89.
- 509 33. Doyon J, Bellec P, Amsel R, et al. Contributions of the basal ganglia and functionally
- related brain structures to motor learning. *Behav Brain Res* 2009; 199: 61-75.
- 511 34. Huotari M, Gogos JA, Karayiorgou M, et al. Brain catecholamine metabolism in catechol-
- 512 O-methyltransferase (COMT)-deficient mice. *Eur J Neurosci* 2002; 15: 246-256.
- 513 35. Parasuraman R, Greenwood PM, Sunderland T. The apolipoprotein E gene, attention, and
 514 brain function. *Neuropsychology* 2002; 16: 254-274.
- 515 36. McFadyen CA, Zeiler FA, Newcombe V, et al. Apolipoprotein E4 polymorphism and
- 516 outcomes from traumatic brain injury: a living systematic review and meta-analysis. J
- 517 *Neurotrauma* 2021; 38: 1124-1136.
- 518 37. Strattan LE, Britsch DRS, Calulot CM, et al. Novel influences of sex and APOE genotype
- 519 on spinal plasticity and recovery of function after spinal cord injury. *eNeuro* 2021; 8. DOI:
- 520 10.1523/ENEURO.0464-20.2021.
- 521 38. Martinez-Gonzalez NA, Sudlow CL. Effects of apolipoprotein E genotype on outcome
- after ischaemic stroke, intracerebral haemorrhage and subarachnoid haemorrhage. *J Neurol Neurosrg Psychiatr* 2006; 77: 1329-1335.
- Math N, Han TS, Lubomirova I, et al. Influences of genetic variants on stroke recovery: a
 meta-analysis of the 31,895 cases. *Neurol Sci* 2019; 40: 2437-2445.

GENETIC POLYMORPHISM AND UL REHABILITATION

SUBRAMANIAN ET AL

526	40.	Levin MF, Kleim JA, Wolf SL. What do motor "recovery" and "compensation" mean in
527		patients following stroke? Neurorehabil Neural Repair 2009; 23: 313-319.
528	41.	Subramanian SK, Chilingaryan G, Sveistrup H, et al. Influence of training environment and
529		cognitive deficits on use of feedback for motor learning in chronic stroke. In: Deutsch J,
530		Wright WG, Weiss PT, eds. Proceedings of the 2015 International Conference on Virtual
531		Rehabilitation (ICVR); June 9–12, 2015; Valencia, Spain. IEEE Publications. doi: 10.1109/
532		ICVR.2015.7358582
533	42.	Liu X, Fang JC, Zhi XY, et al. The influence of val66met polymorphism in brain-derived
534		neurotrophic factor on stroke recovery outcome: A systematic review and meta-analysis.
535		Neurorehabil Neural Repair 2021; 35: 550-560.
536	43.	Kotlega D, Peda B, Zembron-Lacny A, et al. The role of brain-derived neurotrophic factor
537		and its single nucleotide polymorphisms in stroke patients. Neurol Neurochir Pol 2017; 51:
538		240-246.
539	44.	Veerbeek JM, van Wegen E, van Peppen R, et al. What is the evidence for physical therapy
540		poststroke? A systematic review and meta-analysis. PloS one 2014; 9: e87987.
541	45.	Subramanian SK, Birnbaum LA. Genetic polymorphisms negatively impact upper limb
542		motor recovery after stroke-A meta-analysis [abstract]. Stroke 2019; 50(Suppl_1):
543		AWP193.
544	46.	Morton S, Barton CJ, Rice S, et al. Risk factors and successful interventions for cricket-
545		related low back pain: a systematic review. Br J Sports Med 2014; 48: 685-691.
546	47.	Downs SH, Black N. The feasibility of creating a checklist for the assessment of the
547		methodological quality both of randomised and non-randomised studies of health care
548		interventions. J Epidemiol Comm Health 1998; 52: 377-384.

GENETIC POLYMORPHISM AND UL REHABILITATION

SUBRAMANIAN ET AL

48.	Subramanian SK, Caramba SM, Hernandez OL, et al. Is the Downs and Black scale a
	better tool to appraise the quality of the studies using virtual rehabilitation for post-stroke
	upper limb rehabilitation? In: Wright WG, Fluet GG, Subramanian SK, Agmon M, eds.
	Proceedings of the 2019 International Conference on Virtual Rehabilitation (ICVR); July
	22-24, 2019; Tel Aviv, Israel. IEEE Publications. doi: 10.1109/ICVR46560.2019.8994724
49.	O'Connor SR, Tully MA, Ryan B, et al. Failure of a numerical quality assessment scale to
	identify potential risk of bias in a systematic review: a comparison study. BMC Res Notes
	2015; 8: 224.
50.	Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for
	assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
51.	Sterne JAC HJ, Reeves BC on behalf of the development group for ACROBAT-NRSI. A
	Cochrane Risk Of Bias Assessment Tool: for Non-Randomized Studies of Interventions
	$(ACROBAT-NRSI),\ ,\ http://www.bristol.ac.uk/population-health-sciences/centres/cresyda/$
	barr/riskofbias/robins-i/acrobat-nrsi/ (2014, accessed October 01, 2023).
52.	Hedges LV, Olkin I. Combining estimates of correlation co-efficients. Statistical methods
	for meta-analysis. Academic Press, Montreal, QC, 2014, pp.224-244.
53.	Valentine JC, Pigott TD, Rothstein HR. How many studies do you need? A primer on
	statistical power for meta-analysis. J Educ Behav Stat 2010; 35: 215-247.
54.	Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of
	Interventions. 2nd ed. Chichester, UK: John Wiley and Sons, 2019.
55.	DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-
	188.
	 48. 49. 50. 51. 52. 53. 54. 55.

GENETIC POLYMORPHISM AND UL REHABILITATION

- 571 56. Kinney AR, Eakman AM, Graham JE. Novel effect size interpretation guidelines and an
- evaluation of statistical power in rehabilitation research. *Arch Phys Med Rehabil* 2020;
- 573 101: 2219-2226. DOI: 10.1016/j.apmr.2020.02.017.
- 574 57. Chang WH, Bang OY, Shin Y-I, et al. BDNF polymorphism and differential rTMS effects
- on motor recovery of stroke patients. *Brain Stimul* 2014; 7: 553-558.
- 576 58. Chang WH, Uhm KE, Shin Y-I, et al. Factors influencing the response to high-frequency
- 577 repetitive transcranial magnetic stimulation in patients with subacute stroke. *Restor Neurol*
- 578 *Neurosci* 2016; 34: 747-755.
- 579 59. Kim EJ, Park CH, Chang W, et al. The brain-derived neurotrophic factor Val66Met
- polymorphism and degeneration of the corticospinal tract after stroke: a diffusion tensor
 imaging study. *Eur J Neurol* 2016; 23: 76-84.
- 582 60. Park E, Lee J, Chang WH, et al. Differential relationship between microstructural integrity
- in white matter tracts and motor recovery following stroke based on brain-derived
- 584
 neurotrophic factor genotype. Neural Plast 2020; 2020: 5742421. doi: 10.1155/2020/
- 585 5742421.
- 586 61. Shiner CT, Pierce KD, Thompson-Butel AG, et al. BDNF genotype interacts with motor
 587 function to influence rehabilitation responsiveness poststroke. *Front Neurol* 2016; 7: 69.
- 588doi: 10.3389/fneur.2016.00069.
- 589 62. Cramer SC, See J, Liu B, et al. Genetic Factors, Brain Atrophy, and Response to
- 590 Rehabilitation Therapy After Stroke. *Neurorehabil Neural Repair* 2022; 36: 131-139.
- 591 63. Liepert J, Heller A, Behnisch G, et al. Catechol-O-methyltransferase polymorphism
- 592 influences outcome after ischemic stroke: a prospective double-blind study. *Neurorehabil*
- *Neural Repair* 2013; 27: 491-496.

GENETIC POLYMORPHISM AND UL REHABILITATION

SUBRAMANIAN ET AL

594	64.	Chang WH, Park E, Lee J, et al. Association between brain-derived neurotrophic factor
595		genotype and upper extremity motor outcome after stroke. Stroke 2017; 48: 1457-1462.
596	65.	Kim BR, Kim HY, Chun YI, et al. Association between genetic variation in the dopamine
597		system and motor recovery after stroke. Restor Neurol Neurosci 2016; 34: 925-934.
598	66.	Subramanian SK, Yamanaka J, Chilingaryan G, et al. Validity of movement pattern
599		kinematics as measures of arm motor impairment poststroke. Stroke 2010; 41: 2303-2308.
600	67.	Kwakkel G, Wagenaar RC, Koelman TW, et al. Effects of intensity of rehabilitation after
601		stroke. A research synthesis. Stroke 1997; 28: 1550-1556.
602	68.	Lang CE, Lohse KR, Birkenmeier RL. Dose and timing in neurorehabilitation: prescribing
603		motor therapy after stroke. Curr Opin Neurol 2015; 28: 549-555.
604	69.	Page SJ, Schmid A, Harris JE. Optimizing terminology for stroke motor rehabilitation:
605		recommendations from the American Congress of Rehabilitation Medicine Stroke
606		Movement Interventions Subcommittee. Arch Phys Med Rehabil 2012; 93: 1395-1399.
607	70.	McHughen SA, Pearson-Fuhrhop K, Ngo VK, et al. Intense training overcomes effects of
608		the Val66Met BDNF polymorphism on short-term plasticity. Exp Brain Res 2011; 213:
609		415-422.
610	71.	Subramanian S, Chavez M, Gonzalez EA, et al. Estimation of Task Practice Intensity in
611		Individuals with Mild Traumatic Brain Injury [abstract]. Arch Phys Med Rehabil 2021;
612		102: e52-e53.
613	72.	Cirstea MC, Ptito A, Levin MF. Arm reaching improvements with short-term practice
614		depend on the severity of the motor deficit in stroke. ExpBrain Res 2003; 152: 476-488.

GENETIC POLYMORPHISM AND UL REHABILITATION

SUBRAMANIAN ET AL

615	73.	Sullivan JE, Crowner BE, Kluding PM, et al. Outcome measures for individuals with
616		stroke: process and recommendations from the American Physical Therapy Association
617		neurology section task force. Phys Ther 2013; 93: 1383-1396. DOI: 10.2522/ptj.20120492.
618	74.	Rehabilitation Measures Database [Internet]. www.sralab.org/, (2023, accessed September
619		25 2023).
620	75.	Subramanian SK, Cross MK, Hirschhauser CS. Virtual reality interventions to enhance
621		upper limb motor improvement after a stroke: commonly used types of platform and
622		outcomes. Disabil Rehabil Assist Technol 2022;17:107-115.
623	76.	Kwakkel G, Lannin NA, Borschmann K, et al. Standardized measurement of sensorimotor
624		recovery in stroke trials: Consensus-based core recommendations from the Stroke
625		Recovery and Rehabilitation Roundtable. Int J Stroke 2017; 12: 451-461.
626	77.	Weech-Maldonado R. Racial-ethnic differences in nursing home rehabilitation care. In: 6th
627		Annual Medicaid Policy and Research Conference 2007, pp.11-12.
628	78.	Tay MRJ. Hospital readmission in stroke survivors one year versus three years after
629		discharge from inpatient rehabilitation: prevalence and associations in an asian cohort. J
630		Rehabil Med 2021; 53:jrm00208. doi: 10.2340/16501977-2849.
631	79.	Song S, Liang L, Fonarow GC, et al. Comparison of clinical care and in-hospital outcomes
632		of Asian American and white patients with acute ischemic stroke. JAMA Neurol 2019; 76:
633		430-439.
634	80.	Bhandari VK, Kushel M, Price L, et al. Racial disparities in outcomes of inpatient stroke
635		rehabilitation. Arch Phys Med Rehabil 2005; 86: 2081-2086.

GENETIC POLYMORPHISM AND UL REHABILITATION

SUBRAMANIAN ET AL

- 636 81. Shimizu E, Hashimoto K and Iyo M. Ethnic difference of the BDNF 196G/A (val66met)
- 637 polymorphism frequencies: the possibility to explain ethnic mental traits. *Am J Med Genet*
- 638 *B Neuropsychiatr Genet* 2004; 126B: 122-123.
- 639 82. Domschke K, Deckert J, O'donovan MC, et al. Meta-analysis of COMT val158met in panic
- 640 disorder: Ethnic heterogeneity and gender specificity. *Am J Med Genet B Neuropsychiatr*
- 641 *Genet* 2007; 144: 667-673.
- 642 83. Kumar A, Kumar P, Prasad M, et al. Association between apolipoprotein ɛ4 gene
- 643 polymorphism and risk of ischemic stroke: a meta-analysis. Ann Neurosci 2016; 23: 113-
- 644 121.
- 645 84. Zhao F, Yue Y, Jiang H, et al. Shared genetic risk factors for depression and stroke. *Prog*
- 646 *Neuropsychopharmacol Biol Psychiatry* 2019; 93: 55-70.

GENETIC POLYMORPHISM AND UL REHABILITATION

SUBRAMANIAN ET AL

648	Figure legends
649	
650	Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow
651	diagram.
652	
653	Figure 2. Results of meta-analyses examining influence of genetic polymorphisms on upper limb
654	motor impairment quantified using the Fugl-Meyer Assessment, at the end of the intervention
655	period. Larger squares indicate bigger study effect sizes. The diamonds represent pooled effects
656	of results of individual studies. The location of the diamond indicates the estimated effect size
657	and precision of the estimate is indicated by the width of the diamond
658	
659	Figure 3. Results of meta-analyses examining influence of genetic polymorphisms on upper limb
660	motor impairment quantified using the Fugl-Meyer Assessment, at retention testing. Larger
661	squares indicate bigger study effect sizes. The diamonds represent pooled effects of results of
662	individual studies. The location of the diamond indicates the estimated effect size and precision
663	of the estimate is indicated by the width of the diamond.
664	
665	Figure 4. Results of sensitivity analysis (meta-analyses) examining influence of genetic
666	polymorphisms on upper limb motor impairment quantified using the Fugl-Meyer Assessment, at
667	the end of the intervention. Larger squares indicate bigger study effect sizes. The diamonds
668	represent pooled effects of results of individual studies. The location of the diamond indicates
669	the estimated effect size and precision of the estimate is indicated by the width of the diamond.

Table 1 Effect of BDNF polymorphism

Study; Sample size (n); Val/Val and Met Allele distribution and Down's and Black score	Intervention	Rehabilitation provided/ Dose	Outcomes and timing of assessment	Results
Chang et al. 2014; n = 44; Val/Val: n=9; Met allele: n = 35 DBS: 19 (Good)	10 sessions of rTMS over two weeks. Each session had 50 trains of 10 Hz frequency for 5 seconds at 90% RMT	Each train of rTMS was followed by 50 seconds of reaching and grasping exercises. Active and active assisted exercises consisting of range of motion exercises, moving, and grasping and releasing cups and cubes. All participants also received conventional physical (PT) and occupational therapy (OT) sessions, involving gait, fitness, and ADL training for 3 hours each day.	 Upper and lower limb Fugl-Meyer Assessment (FMA) scores Box and Blocks test (BBT). Assessments conducted at baseline, end of the intervention and 2-month retention. 	 <u>FMA</u> UL: Greater change seen in Val/Val group at post (10 points) and retention (23 points) compared to Met alleles (4 and 11 points) respectively (p<0.05). LL: Both groups improved at both assessments with no between group difference. <u>BBT:</u> Greater change seen in Val/Val group (16 blocks) compared to Met alleles (6 blocks; p<0.05) at retention.
Chang et al 2016; n = 62; Val/Val: n=12 Met allele; n= 50 DBS: 18 (fair)	10 sessions of rTMS over two weeks. Each session had 20 trains of 50 stimuli of 10 Hz frequency at 90% RMT	Each train of rTMS was followed by 50 seconds of reaching and grasping exercises. All participants also received conventional PT and OT sessions, involving gait, fitness, and ADL training for 3 hours each day.	 Upper and lower limb and total FMA scores Degree of preserved Corticospinal tract (CST) integrity quantified by Diffusion tensor imaging and presence/absence of MEP in the FDI muscle. 	 20 participants were good responders and 42 were poor responders. Greater proportion of good responders had Val/Val genotype (35%) compared to poor responders (11%). Those with Val/Val genotype had significantly higher change in UL FMA scores (13.7 points) compared to Met alleles (1 point)

			Assessments conducted at baseline and end of the intervention. Patients classified as good or poor responders depending upon the amount of change in UL FMA scores: good responders (≥5points); poor responders (≤4 points)	• Individuals with Val/Val genotype almost twice more likely to have better improvement than those with Met alleles.
Kim et al. 2016a n = 35; Val/Val: n=10 Met allele; n= 25 DBS: 17 (Fair)	No details provided	No information provided	 UL FMA scores Values of fractional anisotropy (FA), axial diffusivity (AD) and radial diffusivity (RD) for CST. Assessments conducted at baseline, T1 (1 month after baseline) and T3 (3 months after baseline) 	 UL FMA scores Greater change in the Val/Val group at T2 (7 points) and T3 (17 points) compared to the Met group (4 and 12 points respectively). Moderate positive correlation with FA Values at T1 (r = 0.78) and T2 (r = 0.72) for the Val/Val group and at T3 (r = 0.59) for the Met group Moderate positive correlation with AD scores at T1 (r = 0.78) and T2 (r = 0.72) for the Val/Val group. Moderate negative correlation with RD values scores at T3 (r = -0.59) for the Met group.
Kim et al. 2016b n = 42; Val/Val: n=26 Met allele; n= 16 DBS: 16 (Fair)	Robotic therapy spread over 2-3 weeks.	Therapy consisted of repeated grasp and release movements of the affected hand and wrist. Participants wore a Hand Wrist Assistive Rehabilitation Device and practiced tasks with real objects as well as virtual reality games (e.g.,	 UL FMA scores Values of percentage change on fMRI signals and activation volume obtained from the ipsi- and contralesional primary sensorimotor cortex 	 No difference in change in UL FMA scores between the <i>Val/Val</i> group at T2 (2.1 points) and the <i>Met</i> group (3.2 points) at the end of therapy. However, the <i>Val/Val</i> group had greater percentage signal change (p = 0.037) and activation volume (p = 0.03) in the ipsilesional primary

		squeezing lemons, moving jewels into a safe, etc.) Tasks focusing on speed, reaction time, force, and range of motion were also practiced.	and dorsal premotor cortex using fMRI. Assessments conducted at baseline, T1 (end of therapy)	sensorimotor cortex compared to the those in the Met group.
Shiner et al. 2016 n = 54; Val/Val: n=27 Met allele: n=27 DBS: 19 (Fair)	Wii based movement therapy (n=40) or modified constraint induced movement therapy (mCIMT, n=14).	10 one-hour long sessions on consecutive weekdays. Sessions targeted movements of the more-affected hand and arm. The Wii group played golf, bowling, baseball, boxing, and tennis using the controller in the more-affected arm. mCIMT group received task- based training on object manipulation focusing on movement speed. Individuals classified into those with low (inability to move >1 block on BBT), moderate (inability to complete Perdue Pegboard Test) and high (ability to complete Perdue Pegboard Test) functional ability.	 Upper limb FMA Wolf Motor Function Test - timed task (WMFT- tt) Motor Activity Log Quality of Movement (MAL-QoM) scores. Assessments conducted at baseline and at the end of the intervention. 	 All participants improved on FMA, WMFT -TT and MALQoM scores at the end of the interventions. Overall, no difference in amount of change in FMA, WMFT-tt and MAL-QoM scores between those with Val/Val and Met alleles. However, subgroup analysis revealed <i>less change</i> in those with Met alleles and moderate (8.9%) or high (13.8%) functional ability on WMFT-tt scores compared to those with Val/Val (25.2% and 37.3% respectively). Similar results were seen on FMA Values <i>less change</i> in those with Met alleles and moderate (7%) or high (2%) functional ability compared to those with Val/Val (10% and 4% respectively).
Chang et al. 2017; n = 97; Val/Val: n=21 Met allele: n=76	Traditional inpatient rehabilitation	Traditional inpatient (2 hrs PT, 1 hr OT) followed by outpatient rehab (1 hr PT, 30 mins OT) or home exs.	 Upper limb FMA scores. Assessments conducted at baseline and T1 (after 3 months). 	Individuals with normal FMA scores or mild and moderate impairment

DBS: 14 (Fair)			Participants classified into 4 categories based upon FMA scores at T1: normal: 66, mild impairment (41–65), moderate impairment (25– 40), and severe 0–24).	 Baseline FMA scores explained 47% of variance in FMA scores at T1 <i>Individuals with severe motor impairment</i> A combination of presence of Met alleles, baseline FMA scores and age explained 59.5% of the variance in FMA scores at T1. Individuals with Met alleles were <i>1.48 times less likely</i> to have better scores on the UL FMA. Smaller proportion of individuals with two (10%) or one Met allele (31%) recovered significantly at T1compared to those with Val/Val genotype (42.9%). Significant correlation between number of Met alleles and FMA
				score at T1 (rho = -0.248, p < 0.05).
Park et al. 2020; DBS: n = 58; Val/Val: n=17 Met allele: n=41 17 (Fair)	Traditional inpatient rehabilitation	All participants received the same dose of PT and OT (3- week intensive inpatient rehabilitation).	 Upper limb FMA scores. FA Values for CST, intrahemispheric connection from M1 to the ventral premotor cortex and corpus callosum (CC). Assessments conducted at baseline and T2 (after 3 months). 	 UL FMA scores Similar mean change seen in UL FMA scores in those with Val/Val (12.6 points) and Met alleles (13.8 points) at T2. In the Val/Val group, moderate negative correlation with FA in contralesional intrahemispheric connection from M1 to the ventral premotor cortex at T2 (r = -0.60; p = 0.024).

				 In those with Met alleles, moderate positive correlation with FA in the in the ipsilesional CST (r=0.47; p= 0.003) and FA in the CC (r=0.41, p =0.011). Overall no difference in amount of
Cramer et al 2022; Task $(n = 206; OT)$ Val/Val: $n = 166; Met$ allele: $n = 40$ DBS: 21 (Good)	c Oriented upper emity training or	Participants were randomized to 30 hrs each of task-oriented upper extremity training (Accelerated Skill Acquisition Program), dose-equivalent occupational therapy, or standard of care.	 Change in Log WMFT- tt. Cerebral atrophy measured using ventricular brain ratio. Assessments carried out at baseline and at end of 12 months 	 Overall, no difference in allount of change in Log WMFT-tt scores between individuals with Met alleles compared to those with Val/Val genotype. Greater cerebral atrophy (p<0.01) seen in individuals with Met alleles compared to those with Val/Val genotype. This enlargement was caused primarily by an enlargement in ventricular volume (p=0.0098).

ADL: Activities of Daily Living ;DBS: Downs and Black Checklist Score; FDI: Flexor Digitorum Indicis; fMRI: Functional Magnetic Resonance Imaging; MEP: Motor Evoked Potential; rTMS: Repetitive Transcranial Magnetic Stimulation; RMT: Resting Motor Threshold.

Study; Sample size (n); distribution and Down's and Black score	Intervention	Rehabilitation provided/ Dose	Outcomes and timing of assessment	Results
		A. Effects of APOE	polymorphism	
Shiner et al. 2016; n = 54; ε4: n = 9; non ε4: n = 45 DBS: 19 (Good)	Wii based movement therapy (n=40) or modified constraint induced movement therapy (mCIMT, n=14).	10 one-hour long sessions on consecutive weekdays. Sessions targeted movements of the more-affected hand and arm. The Wii group played golf, bowling, baseball, boxing, and tennis using the controller in the more-affected arm. mCIMT group received task- based training on object manipulation focusing on movement speed. Individuals classified into those with low (inability to move >1 block on BBT), moderate (inability to complete Perdue Pegboard Test) and high (ability to complete Perdue Pegboard Test) functional ability.	 Upper limb FMA Wolf Motor Function Test - timed task (WMFT- tt) Motor Activity Log Quality of Movement (MAL-QoM) scores. Assessments conducted at baseline and post- intervention. 	 All participants improved on FMA, WMFT-TT and MALQoM scores at the end of the interventions. Overall, no difference in amount of change in FMA and MAL-QoM scores between ε4 carriers and those with non ε4 genotype. ε4 carriers tended to take longer to complete ADL activities (WMFT-tt, p = 0.057) compared to those with non ε4 genotype.
Cramer et al 2022; n = 206; $\epsilon 4: n = 61;$ $non \epsilon 4: n = 145$ DBS: 21 (Good)	Task Oriented upper extremity training or Occupational therapy	Patients were randomized to 30 h each of task-oriented upper extremity training (Accelerated Skill Acquisition Program), dose-equivalent occupational therapy, or standard of care.	 Change in Log WMFT-tt. Cerebral atrophy measured using ventricular brain ratio. 	 Overall, no difference in amount of change in Log WMFT-tt scores between ɛ4 carriers and those with non ɛ4 genotype. No differences seen in cerebral atrophy between individuals with and without the polymorphism.

Table 2 Effect of APOE and COMT polymorphism

		D Effects of COM	Assessments carried out at baseline and at end of 12 months.	
Liepert et al. 2013; n = 83, val/val = 12, met allele: 71 DBS: 19 (Good)	Traditional Rehabilitation	 B. Effects of COM Rehabilitation program included PT, OT, endurance, and strength training. Program was adapted to individual needs of the patient. Details unavailable on total duration of therapy. 	 Rivermead Motor Assessment (RMA) and Barthel Index (BI) scores. RMA scores divided into Gross Function, Leg and trunk and Upper limb function. Assessments carried out at baseline,4 weeks later and at the end of 6 months. 	 <i>RMA scores</i> Individuals with two met alleles showed less improvement in <i>gross function</i> (p = 0.003), <i>leg and trunk function</i> (p = 0.022) as well as <i>upper limb function</i> (p = 0.047). Significant correlation with BI scores at all time points (p <0.001).
Kim et al. 2016 n = 74, val/val = 41, met allele = 33 DBS = 15 (fair)	No details provided	No details provided.	 Total Fugl-Meyer Assessment (FMA) and Functional Independence Measure (FIM) total scores. Assessments carried out at hospital admission, discharge 3- and 6-mos. post- discharge. 	 <i>FMA scores</i> Lower scores at discharge, 3-mos and 6 mons post discharge assessments in those with met alleles (p<0.01) compared to the Val heterozygous group. <i>FIM scores</i> Lower scores at discharge (p < 0.01), 3-mos and 6 mons post discharge (p < 0.05) assessments in those with met alleles compared to the Val heterozygous group.

DBS: Downs and Black Checklist Score; OT: Occupational Therapy; PT: Physical Therapy;

Identification of studies via databases and registers



	No Polymoprhism		Polymorphism		Std. Mean Difference				
Study or Subgroup	85088	80	1055	Moon	80	Total	Weight	IV, Kandoris, 95% CI	_
Charge et al 2014	25.03	14.62	2	15.45	11.78	- 28	14.2%	0.7610.01.1.511	
Chang et al 2010	25.02	11.7	12	15.45	2.0	- 58	16.5%	0.9210 27.1.571	
Kire et al. 28184	26:1	19.2	10	15.6	12.3	- 25	14.0%	0.91 (0.14, 1.93)	
Kim (\$10), 20158	20.8	0.1	- 25	21.5	2.5	18	17.2%	0.0210.59.005	
Parket al 2222	10.2	19.5	17	62.3	19.2	41	16.7%	-6151071.043	
Dhiner et al. 2018	55.12	7.17	27	56.6	5.4	27	15.2%	0.8910 14, 1 24	
Total (95N Cb			101			194	100.0%	0.59 (0.11, 0.06)	
Heterogenetic Tax ² = 0.12; ChP4 18,78; di = 6 (P = 0.08); P = 64% Teatilor overall affect Z = 2.52 (P = 8.01)									





